Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% - Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was down 5.5% during mid-day trading on Tuesday . The stock traded as low as $23.45 and last traded at $23.01. Approximately 14,342 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 224,916 shares. The stock had previously closed at $24.34.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. TD Cowen started coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a "buy" rating for the company. HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Raymond James upgraded shares of Dianthus Therapeutics to a "moderate buy" rating in a research report on Thursday, December 12th. Finally, Oppenheimer upped their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, November 11th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $46.83.

Dianthus Therapeutics Trading Down 4.6 %

The business's 50-day simple moving average is $22.56 and its 200 day simple moving average is $25.02. The company has a market capitalization of $687.09 million, a P/E ratio of -9.24 and a beta of 1.82.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. R Squared Ltd bought a new position in Dianthus Therapeutics during the fourth quarter valued at about $26,000. Quest Partners LLC boosted its position in shares of Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company's stock valued at $31,000 after purchasing an additional 1,124 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Dianthus Therapeutics in the fourth quarter worth approximately $33,000. KBC Group NV bought a new stake in shares of Dianthus Therapeutics during the 4th quarter worth $35,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Dianthus Therapeutics in the 4th quarter worth $59,000. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads